Table 1.
Currently approved biologics for the treatment of psoriasis and their PASI75 response rates
| Target | Name | Type | PASI75% (n) | Timepoint | Approval |
|---|---|---|---|---|---|
| TNFα | Adalimumab [19] | Monoclonal antibody | 71% (578 of 814) | 16 weeks | 2008 |
| Etanercept [20, 21] | Soluble TNFα-receptor | 47% (147 of 311) | 12 weeks | 2004 | |
| Infliximab [22] | Monoclonal antibody | 80% (242 of 301) | 10 weeks | 2006 | |
| Certolizumab Pegol [23] | PEGylated Fab′ fragment | 83% (48 of 58) | 12 weeks | 2018 | |
| IL-12/IL-23p40 | Ustekinumab [24] | Monoclonal antibody | 76% (311 of 411) | 12 weeks | 2009 |
| IL-23p19 | Guselkumab [25] | Monoclonal antibody | 91% (300 of 329) | 16 weeks | 2019 |
| Tildrakizumab [26] | Monoclonal antibody |
A) 62% (192 of 308) B) 79% (236 of 298) |
12 weeks (A) 28 weeks (B) |
2018 | |
| Risankizumab [27] | Monoclonal antibody | 93% (77 of 83) | 12 weeks | 2019 | |
| IL-17A | Ixekizumab [28] | Monoclonal antibody |
A: 98.6% (72 of 73) B: 100% (72) |
12 weeks (A) 24 weeks (B) |
2016 |
| Secukinumab [29] | Monoclonal antibody |
82% (200 of 245), 77% (249 of 323) |
12 weeks | 2015 | |
| IL-17RA | Brodalumab [30] | Monoclonal antibody | 83% (185 of 222) | 12 weeks | 2017 |